Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06046495
Recruiting Phase 1

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

NCT06046495 · tracked via the Priya Life Science USA tracker
Sponsor
Avistone Biotechnology Co., Ltd
Phase
Phase 1
Started
2024-07-08
Last updated
2025-04-23

Condition(s) studied

Non-Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

PLB1004 →

PLB1004: PLB1004 will be orally self-administered by the patient as a mono-therapy.

Study summary

This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dose escalation phase will include patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations, or uncommon mutations. Part 2 includes an expansion phase and the expansion phase will explore one or more dose levels of PLB1004 in NSCLC patients with EGFR Ex20ins mutations, classical mutations, or uncommon mutations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Ability to understand and willingness to sign a written informed consent document; 2. Male or female adult patients 18 years of age or older; 3. Patients should have recovered from toxicities related to prior anti-tumor therapy; 4. Patients should have recovered from the effects of major surgery; 5. Have a documented EGFR mutation by a local test in tissue or plasma; 6. At least 12 weeks life expectancy; 7. Must have at least one measurable lesion per RECIST v 1.1; 8. Sexually active males and females of childbearing potential must agree to take effective contraceptive measures. Exclusion Criteria: 1. Received radiotherapy within 14 days before enrollment; 2. Have significant or uncontrolled systemic disease; 3. Have significant or uncontrolled cardiovascular disease; 4. Have had other diagnosed malignant diseases that required treatment within the past 3 years besides NSCLC; 5. Currently have or had a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia that requires steroid therapy; 6. Have known hypersensitivity to the similar drugs and excipients of PLB1004; 7. Pregnant or lactating women; 8. Have used other experimental drugs within 2 weeks prior to the first dose of PLB1004; 9. Have any condition or illness that could affect the compliance with the protocol.

Primary outcome measure(s)

  • Safety profile of PLB1004 per CTCAE v5.0 — Up to 2 years

Trial sites (7)

FacilityCityRegionStatus
University of California-Davis Sacramento California Recruiting
Research Site Louisville Kentucky Recruiting
Nebraska Cancer Specialists Omaha Nebraska Recruiting
Research Site New York New York Recruiting
Sarah Cannon Research Institute Nashville Tennessee Recruiting
Swedish Health Sciences Seattle Washington Recruiting
Research Site Seattle Washington Recruiting

More Avistone Biotechnology Co., Ltd. trials in the USA

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer Recruiting

Other trials for the same condition

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Active, not recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer Recruiting
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer Active, not recruiting
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06046495 on ClinicalTrials.gov ↗ ← All trials in the USA